Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12Q1/68

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/107017A SYSTEM AND METHOD FOR PROVIDING TEST RESULTS
WO 27.05.2022
Int.Class G16H 50/20
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
20for computer-aided diagnosis, e.g. based on medical expert systems
Appl.No PCT/IB2021/060654 Applicant NORTH-WEST UNIVERSITY Inventor GROBLER, Magdalena Johanna
This invention relates to methods and systems for providing test results, particularly test results from a PCR test of a biological sample, in an automated fashion. The method comprises receiving test data acquired from medical test equipment and processing the test data with a classifier to determine a corresponding test result automatically with a performance measurement. If the performance measurement associated is below a predetermined threshold, the method comprises transmitting the test data to a clinician, receiving a test result from the clinician; and updating the classification database with the test data and the corresponding test result received from the clinician; and if the performance measurement associated with the classification is above the threshold, randomly selecting and transmitting test data to the clinician; receiving a test result from the clinician; and if necessary, updating the classification database with the test data and the corresponding test result from the clinician.
2.WO/2022/109207MASSIVELY PARALLELED MULTI-PATIENT ASSAY FOR PATHOGENIC INFECTION DIAGNOSIS AND HOST PHYSIOLOGY SURVEILLANCE USING NUCLEIC ACID SEQUENCING
WO 27.05.2022
Int.Class C12Q 1/6806
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction assay
Appl.No PCT/US2021/059996 Applicant THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Inventor LOZOYA, Oswaldo, Alonso
The invention generally relates to detecting the presence of a pathogen in a sample, specifically severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and physiological effects on the host with prognostic value, by methods that can simultaneously detect the pathogen and a host's transcriptional response to infection by the pathogen.
3.WO/2022/109267GENOTYPING BY SEQUENCING
WO 27.05.2022
Int.Class G16B 20/20
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
20ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
20Allele or variant detection, e.g. single nucleotide polymorphism detection
Appl.No PCT/US2021/060085 Applicant REGENERON PHARMACEUTICALS, INC. Inventor ABECASIS, Goncalo
The present disclosure provides methods for manufacturing nucleic acid probes for genotyping by sequencing, methods for genotyping a DNA sample by sequencing using a set of nucleic acid probes, and systems for carrying out such methods.
4.WO/2022/109537APPARATUS AND METHODS FOR MOLECULAR DIAGNOSTICS
WO 27.05.2022
Int.Class C12M 1/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
1Apparatus for enzymology or microbiology
34Measuring or testing with condition measuring or sensing means, e.g. colony counters
Appl.No PCT/US2021/072418 Applicant NUCLEIN, LLC Inventor CROCKETT, Richard
This disclosure relates to apparatus and methods for molecular diagnostics. Certain embodiments include a piston cycled from a first position proximal to a first end of a housing, to a second position proximal to a second end of the housing, and back to the first position proximal to the first end of the housing. In some embodiments, the present disclosure relates to devices, methods, and systems for molecular diagnostics that do not comprise a piston.
5.WO/2022/107136METHODS AND BIOMARKERS FOR DIAGNOSTICS, DISEASE MONITORING, PERSONALIZED DRUG DISCOVERY AND TARGETED THERAPY IN GLIOMA PATIENTS
WO 27.05.2022
Int.Class C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
Appl.No PCT/IL2021/051370 Applicant BAR-ILAN UNIVERSITY Inventor FRENKEL-MORGENSTERN, Milana
Novel powerful methods for identifying, monitoring, and treating conditions associated with omics-discoverable features in human subjects, and particularly conditions such as malignant tumors are provided.
6.WO/2022/108372METHOD FOR MANUFACTURING BRAIN ORGANOIDS AND SCREENING METHOD FOR THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES USING SAME
WO 27.05.2022
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Appl.No PCT/KR2021/017023 Applicant SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION Inventor MOOK, In Hee
The present invention relates to a method for manufacturing brain organoids and a screening method for a therapeutic agent for neurodegenerative diseases using same and, more particularly, to a method for manufacturing brain organoids of which physiological/pathological characteristics expressed in the brain of a subject are embodied at high levels, and a screening method for a therapeutic agent for neurodegenerative diseases using same.
7.WO/2022/107006METHODS AND DEVICES FOR RAPID DETECTION OF COVID-19 AND OTHER PATHOGENS
WO 27.05.2022
Int.Class C12Q 1/6844
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6844Nucleic acid amplification reactions
Appl.No PCT/IB2021/060631 Applicant KHALIFA UNIVERSITY OF SCIENCE AND TECHNOLOGY Inventor ALAZZAM, Anas
A device (10) and method for detecting COVID-19 and other pathogens includes a sample compartment (26) contained within an interior of the device and having multiple apertures (32) for releasably receiving one or more test tubes (42) containing a biological sample. A bottom portion (48) of the test tube (42) is contained within the interior (22) of the device (10) and a top portion (46) of the test tube (42) is exposed to atmosphere. The biological sample is lysed using the device (10); the lysed sample is mixed with one or more primers and then amplification (RT-LAMP) is performed using the device (10). A thermally conductive material on or in proximity to the sample compartment (26) can facilitate precise heating of the compartment (26) and sample. A thermally insulative material can be inside the interior of the compartment housing (30). Multiple samples can be tested simultaneously. The results can be interpreted by a color change of the sample. The device (10) is efficient, portable, reliable, and re-usable.
8.WO/2022/108701COMPOSITIONS AND METHODS FOR SEQUENCING USING FLUOROPHORES AND QUENCHERS OR DONORS
WO 27.05.2022
Int.Class C12Q 1/6869
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6869Methods for sequencing
Appl.No PCT/US2021/055958 Applicant ILLUMINA, INC. Inventor MANDELL, Jeffrey
A method is provided that includes adding, using a polymerase coupled to a substrate, nucleotides in a solution to a first polynucleotide using at least a sequence of a second polynucleotide. The method includes separating, using labels respectively coupled to the nucleotides, quenchers from respective fluorophores. The method includes then detecting a sequence in which the polymerase adds the nucleotides to the first polynucleotide using at least fluorescence from the respective fluorophores.
9.WO/2022/109181METHODS AND COMPOSITIONS FOR ANALYZING IMMUNE INFILTRATION IN CANCER STROMA TO PREDICT CLINICAL OUTCOME
WO 27.05.2022
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Appl.No PCT/US2021/059959 Applicant 10X GENOMICS, INC. Inventor BAUMGARTNER, Florian
Provided herein are methods for analyzing immune cell infiltration in a cancer stromal region of a biological sample obtained from a subject using machine learning modules. For example, the methods may include (a) identifying a cancerous region or an analyte associated with the cancerous region in the biological sample; (b) identifying a stromal region or an analyte associated with the stromal region in the biological sample; (c) identifying one or more immune cells or an analyte associated with an immune cell in one or more locations in the biological sample; and (d) using (i) the identified cancerous and stromal regions or associated analytes thereof in the biological sample and (ii) the identified one or more immune cells or associated analytes thereof to analyze immune cell infiltration in the cancer stromal region of the biological sample obtained from the subject.
10.WO/2022/109196MULTIPLEXED IMAGING WITH NANOBODY PROBES
WO 27.05.2022
Int.Class C12Q 1/6804
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6804Nucleic acid analysis using immunogens
Appl.No PCT/US2021/059982 Applicant AKOYA BIOSCIENCES, INC. Inventor ZHENG, Yi
Methods include (a) contacting a biological sample with a composition featuring a plurality of different types of probes, where each type of probe of the plurality of different types of probes includes a detection moiety that selectively binds to a different type of protein target in the sample, a nanobody bound to the detection moiety, and an oligonucleotide linked to the nanobody and featuring an oligonucleotide sequence, where the oligonucleotide sequence of each type of probe is different from the oligonucleotide sequences of each of the other types of probes of the plurality of probes; and (b) contacting the sample with a set of one or more different types of optical labels, where each different type of optical label of the set of optical labels includes an oligonucleotide that selectively hybridizes to only one type of probe. Nanobodies can be labelled accurately with fluorescent molecules, thereby allowing a more accurate imaging of the targets.